Veru Inc (NAS:VERU)

$ 0.7448 0.0102 (1.39%) Market Cap: 107.53 Mil Enterprise Value: 92.06 Mil PE Ratio: 0 PB Ratio: 2.83 GF Score: 46/100

Q3 2024 Veru Inc Earnings Call Transcript
Aug 08, 2024

$0.8101 (+5.34%)

Earnings
Q2 2024 Veru Inc Earnings Call Transcript
May 08, 2024

$1.43 (-12.27%)

Earnings
Q1 2024 Veru Inc Earnings Call Transcript
Feb 08, 2024

$0.4111 (-6.57%)

Earnings
Veru Inc to Discuss Financing and Strategy to Prioritize the Development of Enobosarm Transcript
Jan 04, 2024
Q3 2023 Veru Inc Earnings Call Transcript
Aug 10, 2023

$1.09 (+0.93%)

Earnings
Veru Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Q2 2023 Veru Inc Earnings Call Transcript
May 11, 2023

$1.23 (-17.45%)

Earnings
Q1 2023 Veru Inc Earnings Call Transcript
Feb 09, 2023

$3.97 (-22.61%)

Earnings
Q4 2022 Veru Inc Earnings Call Transcript
Dec 05, 2022

$5.82 (+5.82%)

Earnings
Q3 2022 Veru Inc Earnings Call Transcript
Aug 11, 2022

$16.01 (+36.02%)

Earnings
Q2 2022 Veru Inc Earnings Call Transcript
May 12, 2022

$9.03 (+10.66%)

Earnings
Veru Inc Sabizabulin for COVID Update Call Transcript
Apr 11, 2022
Q1 2022 Veru Inc Earnings Call Transcript
Feb 09, 2022

$6 (+6.19%)

Earnings
Q4 2021 Veru Inc Earnings Call Transcript
Dec 02, 2021

$6.95 (+0.58%)

Earnings
Veru Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 21, 2021
Q3 2021 Veru Inc Earnings Call Transcript
Aug 12, 2021

$7.44 (+6.90%)

Earnings
Q2 2021 Veru Inc Earnings Call Transcript
May 12, 2021

$7.24 (-3.34%)

Earnings
Q1 2021 Veru Inc Earnings Call Transcript
Feb 10, 2021

$19.23 (-0.21%)

Earnings
Veru Inc. - Special Call Transcript
Feb 08, 2021
Q4 2020 Veru Inc Earnings Call Transcript
Dec 09, 2020

$3.89 (+19.88%)

Earnings
Q3 2020 Veru Inc Earnings Call Transcript
Aug 13, 2020

$2.73 (-9.90%)

Earnings
Q2 2020 Veru Inc Earnings Call Transcript
May 13, 2020

$3.97 (+12.46%)

Earnings
Q1 2020 Veru Inc Earnings Call Transcript
Feb 12, 2020

$4.32 (+1.41%)

Earnings
Q4 2019 Veru Inc Earnings Call Transcript
Dec 12, 2019

$2.4 (-2.04%)

Earnings
Q3 2019 Veru Inc Earnings Call Transcript
Aug 08, 2019

$2.12 (-7.02%)

Earnings
Q2 2019 Veru Inc Earnings Call Transcript
May 15, 2019

$1.58 (-5.95%)

Earnings
Q1 2019 Veru Inc Earnings Call Transcript
Feb 13, 2019

$1.36 (-8.72%)

Earnings

Veru Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript

Sep 21, 2021 / 05:15PM GMT

Release Date Price: $8.71 (+2.96%)

Transcript

Leland Gershell

Oppenheimer & Co. - Analyst

Good afternoon, everyone, and welcome to another session here on the second day of Oppenheimer's Virtual Fall Healthcare Summit. We are very delighted to have Veru Pharma with us for this session. If you follow our research, you'll know that we not only cover the stock with an outperform rating, but really see this as a top pick within our universe.

On behalf of the Company, we have Founder and CEO, Dr. Mitch Steiner, who will be walking us through all the various programs that the Company is pursuing. And if you have any questions, please submit to us through the online platform, and I'll do my best to ask those. And with that, I'll turn it over to Mitch.

Mitch Steiner

Very Inc. - Chairman, President & CEO

Great. Thank you. Thank you, Leland, and thank you to Oppenheimer for inviting us to your investment conference. So Veru is an oncology biopharmaceutical company, and we are focused on prostate cancer, breast cancer, but we're much more than that. Before I begin, I will be making some forward

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.